How were GlobeImmune's earnings last quarter?

GlobeImmune, Inc. (OTCMKTS:GBIM) announced its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.12. The biopharmaceutical company had revenue of $0.94 million for the quarter.

What other stocks do shareholders of GlobeImmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlobeImmune investors own include OHR Pharmaceutical (OHRP) , Novavax (NVAX) , Premier Gold Mines (PG) , Algonquin Power & Utilities (AQN) , Nordic American Tankers (NAT) , (BAA) (BAA) , Petróleo Brasileiro S.A. - Petrobras (PBR) , Pengrowth Energy (PGH) , Absolute Software Co. (ABT.TO) (ABT) and Alacer Gold (ASR) .

How do I buy shares of GlobeImmune?

Shares of GBIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:GBIM

GlobeImmune (GBIM) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free GBIM Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials Short Interest

Get GlobeImmune alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About GlobeImmune Stock (OTCMKTS:GBIM)

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

GBIM Stock News Headlines

July 18, 2023 | investing.com

Bubang Co Ltd (014470)

July 18, 2023 | investing.com

Nihon Knowledge Co Ltd (5252)

April 19, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

April 21, 2023 | nasdaq.com

Nuvista Energy Breaks Below 200-Day Moving Average - Notable for NVA

January 9, 2023 | sg.finance.yahoo.com

GlobeImmune, Inc. (GBIM) stock historical prices & data – Yahoo Finance

September 15, 2022 | reuters.com

GBIM.PK - GlobeImmune Inc | Stock Price & Latest News | Reuters

See More Headlines

Receive GBIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlobeImmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/12/2016
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:GBIM
Previous Symbol: NASDAQ:GBIM
CUSIP: N/A
CIK: 1245104
Web: www.globeimmune.com
Phone: (720) 667-2300
Fax: 303-625-2710
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: -194.16

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. C. Jeffrey Dekker CPA (Age 59)
President, Vice President of Finance, Treasurer & Secretary
Comp: $200.05k
Dr. Richard C. Duke
Scientific Founder & Member of Scientific Advisory Board
Dr. Donald Bellgrau
Scientific Founder & Chairman of The Scientific Advisory Board

Key Competitors

View All Competitors

GBIM Stock Analysis - Frequently Asked Questions

How were GlobeImmune's earnings last quarter?: GlobeImmune, Inc. (OTCMKTS:GBIM) announced its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.12. The biopharmaceutical company had revenue of $0.94 million for the quarter.
What other stocks do shareholders of GlobeImmune own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GlobeImmune investors own include OHR Pharmaceutical (OHRP), Novavax (NVAX), Premier Gold Mines (PG), Algonquin Power & Utilities (AQN), Nordic American Tankers (NAT), (BAA) (BAA), Petróleo Brasileiro S.A. - Petrobras (PBR), Pengrowth Energy (PGH), Absolute Software Co. (ABT.TO) (ABT) and Alacer Gold (ASR).
How do I buy shares of GlobeImmune?: Shares of GBIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GBIM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial